Entera Bio (NASDAQ:ENTX) Shares Up 7.8% – What’s Next?

Posted by Francis Steltz on Oct 19th, 2026

Entera Bio Ltd. (NASDAQ:ENTX – Get Free Report) shares rose 7.8% during trading on Monday. The company traded as high as $2.89 and last traded at $2.89. Approximately 661,753 shares were traded during mid-day trading, a decline of 34% from the average daily volume of 1,005,796 shares. The stock had previously closed at $2.68.

Wall Street Analyst Weigh In

ENTX has been the topic of several research reports. Leerink Partners started coverage on Entera Bio in a research report on Friday, September 18th. They set an “outperform” rating and a $9.00 price target on the stock. Cantor Fitzgerald assumed coverage on Entera Bio in a report on Tuesday, September 22nd. They issued an “overweight” rating for the company. UBS Group set a $9.00 price objective on Entera Bio in a report on Friday, September 18th. HC Wainwright reissued a “buy” rating on shares of Entera Bio in a research report on Wednesday, June 24th. Finally, Guggenheim assumed coverage on shares of Entera Bio in a report on Thursday, September 24th. They set a “buy” rating and a $11.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Entera Bio presently has an average rating of “Moderate Buy” and a consensus price target of $9.60.

View Our Latest Research Report on Entera Bio

Entera Bio Stock Up 8.0%

The stock’s fifty day simple moving average is $2.88 and its two-hundred day simple moving average is $2.02. The firm has a market cap of $503.50 million, a PE ratio of -8.27 and a beta of 1.40.

Entera Bio (NASDAQ:ENTX – Get Free Report) last released its earnings results on Friday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.06). On average, equities research analysts anticipate that Entera Bio Ltd. will post -0.40 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Entera Bio stock. Seven Fleet Capital Management LP raised its stake in shares of Entera Bio Ltd. (NASDAQ:ENTX – Free Report) by 51.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 205,542 shares of the company’s stock after buying an additional 70,224 shares during the quarter. Seven Fleet Capital Management LP owned about 0.42% of Entera Bio worth $228,000 at the end of the most recent quarter. 14.11% of the stock is owned by hedge funds and other institutional investors.

Entera Bio Company Profile

(Get Free Report)

Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered biologic medicines. The company’s proprietary platform is designed to enable the oral administration of large-molecule therapies, including peptides and proteins that are traditionally delivered by injection.

Entera Bio’s pipeline has included EB613, an oral formulation of parathyroid hormone fragment (teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral parathyroid hormone product intended for hypoparathyroidism.